Full-Time
eProcurement services for streamlined purchasing
$24.54 - $38.34/hr
Junior, Mid
Company Does Not Provide H1B Sponsorship
Boulder, CO, USA
Agilent Technologies provides electronic procurement services that help businesses streamline their purchasing processes. Their main offerings include a suite of eProcurement services that allow clients to integrate their pricing into existing platforms, access a hosted catalog, and conduct transactions without paper. This system is designed to help businesses quickly find and buy the products they need at the right price, making the purchasing process easier and more efficient. Agilent stands out from competitors by focusing on automation, faster connectivity, and simplified workflows, which leads to lower costs and increased profitability for clients. The goal of Agilent Technologies is to enhance business productivity through these tailored eProcurement solutions, serving a wide range of clients who value their expertise and reliability.
Company Size
10,001+
Company Stage
IPO
Headquarters
Santa Clara, California
Founded
1999
Help us improve and share your feedback! Did you find this helpful?
Remote Work Options
Performance Bonus
Stock Options
Agilent has acquired Sigsense Technologies, a startup that uses artificial intelligence and power monitoring to optimize lab operations.
CHARLOTTETOWN, Prince Edward Island and SANTA CLARA, California – July 22, 2024 BIOVECTRA Inc. and Agilent Technologies, Inc. (NYSE: A) today announced the signing of an agreement for Agilent to acquire BIOVECTRA, a Canadian-based Contract Development and Manufacturing Organization, from H.I.G. Capital for $925 million. The acquisition provides the ability to expand the range of [...]Read More...
RareCyte, a Seattle, WA-based Life Sciences company providing precision biology platforms including instruments, reagents, software, and services, raised $20M in funding
SAN CARLOS, Calif.--(BUSINESS WIRE)--Elegen, the leader in next-generation DNA synthesis and production, today announced a Series B financing of $35 million led by Triatomic Capital. Also joining the round are strategic investors GSK, which recently entered a collaboration and licensing agreement with Elegen to use their proprietary cell-free DNA manufacturing technology in developing GSK’s vaccines and medicines, and John Ballantyne, co-founder of Aldevron. Elegen’s current investors, including Andreessen Horowitz (a16z Bio + Health), KdT Ventures, 8VC, Digitalis Ventures, ACVC Partners, Alix Ventures, AME Cloud Ventures and Agilent Technologies, also participated. The new funds will accelerate the extension of the company’s rapidly growing ENFINIA™ DNA product line across clinical workflows providing turnkey production of GMP-compliant DNA for clinical development of genetic medicines. “The age of genetic medicines is here, but these powerful modalities require innovative new manufacturing approaches to supply the critical input DNA material for rapid discovery, development and then wide-scale production,” said Matthew Hill, Ph.D., Elegen Founder and CEO. “With this investment, we will continue to push the boundaries of DNA synthesis to accelerate upstream discovery and enable rapid and streamlined deployment of new clinical modalities.”
The firm said it also plans to use the money, which brings its total raised to $60 million, to establish a dedicated manufacturing facility in the UK.